Reference article — last reviewed 2026
Abstract
The New Zealand green-lipped mussel (Perna canaliculus) is a marine bivalve whose lipid- and glycosaminoglycan-rich extracts have been investigated as a nutraceutical for inflammatory and degenerative joint disease since the 1980s. A 2006 systematic review of human supplementation trials concluded that the evidence at that time was inconsistent. Since then, several methodologically improved canine clinical trials have addressed the specific question of efficacy in dogs with osteoarthritis, with more uniformly positive results than the earlier human literature. This article reviews the post-2006 canine trial evidence, the proposed bioactive components, and the dose-response considerations relevant to clinical use.
1. Composition and proposed bioactive components
Green-lipped mussel powders and lipid extracts are complex matrices containing several biologically plausible joint-active constituents:
- Long-chain omega-3 fatty acids, including eicosapentaenoic acid (EPA) and the more unusual furan fatty acids and eicosatetraenoic acids characteristic of the species.
- Glycosaminoglycans and chondroitin-sulphate-rich proteoglycans, which provide oral substrates relevant to articular cartilage matrix.
- Antioxidant and chelating peptides isolated from mussel hydrolysates.
- 5-Lipoxygenase pathway inhibitors, demonstrated in vitro and proposed to underlie reductions in leukotriene-mediated inflammation.
The 5-lipoxygenase inhibition mechanism in particular has been advanced as a basis for the clinical effect, complementing the better-known cyclooxygenase-pathway pharmacology of NSAIDs (Whitehouse et al., 1997).
2. The 2006 systematic review and its successors
A 2006 systematic review by Cobb and Ernst pooled the human-trial evidence available at that time and concluded that the evidence for green-lipped mussel in rheumatoid and osteoarthritis was "limited and inconsistent" (Cobb & Ernst, 2006). Several caveats applied: studies were small, formulations were heterogeneous, blinding was variable, and outcome measures differed across trials.
Subsequent canine work has been better controlled than much of the earlier human literature, in part because dog trials can use objective force-plate gait analysis as a primary outcome.
3. Canine clinical trials
3.1 Bui & Bierer (2003)
A randomised, double-blinded, placebo-controlled trial in 31 dogs with osteoarthritis administered a green-lipped mussel preparation incorporated into a complete food. Owner-assessed and veterinarian-assessed lameness scores improved significantly relative to placebo over 6 weeks (Bui & Bierer, 2003).
3.2 Pollard et al. (2006)
A New Zealand multicentre randomised trial (n = 81 dogs) found significant reductions in joint swelling, joint pain, and crepitus in dogs supplemented with a freeze-dried green-lipped mussel powder over 6 weeks compared with placebo. Adverse events were rare and mild (Pollard et al., 2006).
3.3 Hielm-Björkman et al. (2009)
A Finnish randomised trial in 45 dogs comparing green-lipped mussel supplementation with carprofen monotherapy and with placebo found significant lameness improvement in both treatment arms compared with placebo, although carprofen produced larger and faster effects. Importantly, the mussel-supplemented group showed continued benefit beyond the supplementation window, suggesting a possible carry-over effect (Hielm-Björkman et al., 2009).
3.4 Vijarnsorn et al. (2019)
A randomised trial comparing the green-lipped-mussel-derived lipid extract PCSO-524 with the COX-2-selective NSAID firocoxib in dogs with osteoarthritis found that both treatments produced significant clinical improvement, with the mussel extract delivering an effect size approaching that of the pharmacological comparator over a 56-day course. The study supports the use of stabilised lipid-extract formulations as a comparator-grade nutraceutical option (Vijarnsorn et al., 2019).
3.5 Rialland et al. (2013)
A controlled trial in 23 dogs evaluated a diet incorporating a green-lipped mussel extract over 90 days. Force-plate gait analysis showed objective improvements in peak vertical force in supplemented dogs, accompanied by improvements in subjective lameness scores. The use of objective force-plate methodology strengthened internal validity (Rialland et al., 2013).
4. Dose, formulation, and bioavailability
The dose used across most positive canine trials clusters around 10–50 mg/kg body weight per day of green-lipped mussel powder, equivalent to approximately 0.1–0.5 g/kg of mussel meat. Lipid-extract preparations require lower doses (commonly 5–15 mg/kg/day) because the active lipid fraction is concentrated.
Formulation matters: thermal processing during manufacture can degrade the labile lipid fraction. Trials using stabilised, low-temperature-processed preparations have generally produced more consistent results than those using freely heated powders (Treschow et al., 2007).
5. Safety and tolerability
Across the canine trial literature, green-lipped mussel preparations have been well tolerated. Reported adverse events have been confined to mild gastrointestinal upset (transient soft stools, occasional vomiting) at doses above the typical range. Hypersensitivity reactions are theoretically possible in dogs with shellfish allergy and have been reported anecdotally; clinicians should screen the history before initiation.
6. Comparison with omega-3 supplementation alone
A natural question is whether green-lipped mussel offers benefits beyond purified omega-3 fatty acid supplementation, given that fish oil is better characterised and inexpensive. The mechanistic argument for additional benefit rests on (1) the unique furan fatty acids and other lipid species in mussel extracts not present in fish oil, (2) the glycosaminoglycan content, and (3) the antioxidant peptide content. Direct head-to-head canine trials comparing isolated EPA/DHA with green-lipped mussel preparations are limited; existing data do not establish clear superiority in either direction.
7. Conclusion
The evidence base for green-lipped mussel in canine osteoarthritis has matured considerably since the equivocal 2006 systematic review of human-trial data. Multiple independently conducted, randomised, placebo-controlled canine trials — including studies using objective force-plate methodology — have shown small-to-moderate but reproducible benefits in lameness and function. Effect sizes are smaller than those of NSAIDs but comparable to those of other nutraceuticals such as omega-3-enriched diets. Green-lipped mussel preparations are a reasonable evidence-based option as part of a multimodal management approach to canine osteoarthritis, with selection guided by formulation quality and dose adequacy.
References
- Whitehouse MW, Macrides TA, Kalafatis N, Betts WH, Haynes DR, Broadbent J. Anti-inflammatory activity of a lipid fraction (Lyprinol) from the NZ green-lipped mussel. Inflammopharmacology. 1997;5(3):237–246. PMID: 17638133.
- Bui LM, Bierer TL. Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs. Vet Ther. 2003;4(4):397–407. PMID: 15136981.
- Cobb CS, Ernst E. Systematic review of a marine nutraceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin Rheumatol. 2006;25(3):275–284. PMID: 16220229.
- Pollard B, Guilford WG, Ankenbauer-Perkins KL, Hedderley D. Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. N Z Vet J. 2006;54(3):114–118. PMID: 16751841.
- Treschow AP, Hodges LD, Wright PFA, et al. Novel anti-inflammatory omega-3 PUFAs from the New Zealand green-lipped mussel, Perna canaliculus. Comp Biochem Physiol B Biochem Mol Biol. 2007;147(4):645–656. PMID: 17543561.
- Hielm-Björkman A, Tulamo RM, Salonen H, Raekallio M. Evaluating complementary therapies for canine osteoarthritis—Part I: Green-lipped mussel (Perna canaliculus). Evid Based Complement Alternat Med. 2009;6(3):365–373. PMID: 18955269.
- Vijarnsorn M, Kwananocha I, Kashemsant N, et al. The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis. BMC Vet Res. 2019;15(1):349. PMID: 31623621.
- Rialland P, Bichot S, Lussier B, Moreau M, Beaudry F, del Castillo JR, Gauvin D, Troncy E. Effect of a diet enriched with green-lipped mussel on pain behavior and functioning in dogs with clinical osteoarthritis. Can J Vet Res. 2013;77(1):66–74. PMID: 23814358.